<DOC>
	<DOCNO>NCT00194116</DOCNO>
	<brief_summary>Double-Blind , Placebo-Controlled Divalproex Sodium ER Bipolar I Bipolar II Depression Previously Diagnosed Treated Recurrent Major Depression : This study recruit male female age 18 - 70 currently meet diagnostic criterion bipolar I bipolar II disorder currently experience episode major depression . Patients randomize double-blind treatment divalproex sodium ER placebo remain study six week . This six-week double-blind treatment period follow open-label treatment period six month duration . This study sponsor Abbott Laboratories .</brief_summary>
	<brief_title>Double-blind , Placebo-Controlled Divalproex Sodium ER Bipolar I Bipolar II Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Subject must give consent participate study sign date IRB approve write informed consent form prior initiation study procedure Subject must age 18 70 Subject must diagnosis bipolar I II . Subject must currently depress confirm MiniInternational Neuropsychiatric Interview ( MINI ) Subject must baseline MontgomeryAsberg Depression Scale ( MADRS ) score &gt; 19 Young Mania Rating Scale ( YMRS ) score &lt; 12 Women childbearing potential must nonpregnant/nonlactating use adequate contraception sexually active Subject must use concomitant psychotropic medication acute phase except prn benzodiazepine Subjects lack capacity provide inform consent Subject currently previously use divalproex DvpxER Subject serious suicide risk medically unstable condition judge investigator Subject alcohol , cocaine , cannabis dependence within 3 month study entry Subject cocaine , hallucinogen , opiate , crystal methamphetamine , MMDA abuse within 3 month study entry</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>